Evaluation of the effects of dexmedetomidine infusion on oxygenation and lung mechanics in morbidly obese patients with restrictive lung disease

Ahmed Hasanin, Kareem Taha, Bassant Abdelhamid, Ayman Abougabal, Mohamed Elsayad, Amira Refaie, Sarah Amin, Shaimaa Wahba, Heba Omar, Mohamed Maher Kamel, Yaser Abdelwahab, Shereen M Amin, Ahmed Hasanin, Kareem Taha, Bassant Abdelhamid, Ayman Abougabal, Mohamed Elsayad, Amira Refaie, Sarah Amin, Shaimaa Wahba, Heba Omar, Mohamed Maher Kamel, Yaser Abdelwahab, Shereen M Amin

Abstract

Background: Dexmedetomidine infusion improves oxygenation and lung mechanics in patients with chronic obstructive lung disease; however, its effect in patients with restrictive lung disease has not been thoroughly investigated yet. The aim of this work was to evaluate the effects of dexmedetomidine infusion on oxygenation and lung mechanics in morbidly obese patients with restrictive lung disease.

Methods: Forty-two morbidly obese patients scheduled for bariatric surgery were included in the study. Patients were randomized to receive either dexmedetomidine infusion at a bolus dose of 1mcg/Kg followed by infusion at 1 mcg/Kg/hour for 90 min (Dexmedetomidine group), or normal saline infusion (Control group). Both groups were compared with regard to: oxygenation {P/F ratio: PaO2/fraction of inspired oxygen (FiO2)}, lung compliance, dead space, plateau pressure, blood pressure, and heart rate.

Results: Dexmedetomidine group showed significant improvement of the PaO2/FiO2 ratio, and higher lung compliance compared to control group by the end of drug infusion. Dexmedetomidine group demonstrated decreased dead space, plateau pressure, blood pressure, and heart rate compared to control group by the end of drug infusion.

Conclusion: A 90-min dexmedetomidine infusion resulted in moderate improvement in oxygenation and lung mechanics in morbidly obese patients with restrictive lung disease.

Trial registration: clinicaltrials.gov : NCT02843698 on 20 July 2016.

Keywords: Dexmedetomidine; Morbidly obese; Oxygenation.

Conflict of interest statement

Ethical approval from Cairo university hospitals research committee was obtained (N-12-2016). Written informed consents were obtained from participants before inclusion.

Not applicable.

The authors declare that they have no competing interests.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Patient recruitment chart
Fig. 2
Fig. 2
Plateau pressure. * denotes significance between both groups
Fig. 3
Fig. 3
Systolic and diastolic blood pressure. * denotes significance between both groups, † denotes significance compared to the baseline reading within dexmedetomidine group
Fig. 4
Fig. 4
Heart rate. * denotes significance between both groups, † denotes significance compared to the baseline reading within dexmedetomidine group

References

    1. Groeben H, Mitzner W, Brown RH. Effects of the alpha2-adrenoceptor agonist dexmedetomidine on bronchoconstriction in dogs. Anesthesiology. 2004;100:359–363. doi: 10.1097/00000542-200402000-00026.
    1. Unal Y, Pampal HK, Arslan M, Demirel CB, Alkan M. The effects of dexmedetomidine on pulmonary artery pressure in experiment. Bratisl Lek ListyBratisl Lek Listy. 2014;115:272–274.
    1. Lee SH, Kim N, Lee CY, Ban MG, Oh YJ. Effects of dexmedetomidine on oxygenation and lung mechanics in patients with moderate chronic obstructive pulmonary disease undergoing lung cancer surgery. Eur J Anaesthesiol. 2016;33:1–8. doi: 10.1097/EJA.0000000000000405.
    1. Heil LBB, Santos CL, Santos RS, et al. The effects of short-term Propofol and Dexmedetomidine on lung mechanics, histology, and biological markers in experimental obesity. Anesth Analg. 2016;122:1015–1023. doi: 10.1213/ANE.0000000000001114.
    1. Ortiz VE, Kwo J. Obesity: physiologic changes and implications for preoperative management. BMC Anesthesiol. 2015;15:97. doi: 10.1186/s12871-015-0079-8.
    1. De Baerdemaeker L, Margarson M. Best anaesthetic drug strategy for morbidly obese patients. Curr Opin Anaesthesiol. 2015;29:119–128. doi: 10.1097/ACO.0000000000000286.
    1. Fernandez-Bustamante A, Hashimoto S, Serpa Neto A, Moine P, Vidal Melo MF, Repine JE. Perioperative lung protective ventilation in obese patients. BMC Anesthesiol. 2015;15:56. doi: 10.1186/s12871-015-0032-x.
    1. Hardman JG, Aitkenhead AR. Estimating alveolar dead space from the arterial to end-tidal CO (2) gradient: a modeling analysis. Anesth Analg. 2003;97:1846–1851. doi: 10.1213/01.ANE.0000090316.46604.89.
    1. Kobelt P, Burke K, Renker P. Evaluation of a standardized sedation assessment for opioid Administration in the Post Anesthesia Care Unit. Pain Manag Nurs. 2014;15:672–681. doi: 10.1016/j.pmn.2013.11.002.
    1. Xia R, Yin H, Xia Z, Mao Q, Chen G, Xu W. Effect of intravenous infusion of dexmedetomidine combined with inhalation of isoflurane on arterial oxygenation and intrapulmonary shunt during single-lung ventilation. Cell Biochem Biophys. 2013;67:1547–1550. doi: 10.1007/s12013-013-9659-8.
    1. Xia R, Xu J, Yin H, et al. Intravenous infusion of Dexmedetomidine combined isoflurane inhalation reduces oxidative stress and potentiates hypoxia pulmonary vasoconstriction during one-lung ventilation in patients. Mediat Inflamm. 2015;2015:238041. doi: 10.1155/2015/238041.
    1. Huang S-Q, Zhang J, Zhang X-X, et al. Can Dexmedetomidine Improve Arterial Oxygenation and Intrapulmonary Shunt during One-lung Ventilation in Adults Undergoing Thoracic Surgery? A Meta-analysis of Randomized, Placebo-controlled Trials. Chin Med J. 2017;130:1707. doi: 10.4103/0366-6999.209891.
    1. Zhang W, Zhang S, Li B, Sun M, Zhang J. Paravertebral dexmedetomidine as an adjuvant to ropivacaine protects against independent lung injury during one-lung ventilation: a preliminary randomized clinical trial. BMC Anesthesiol. 2018;18:67. doi: 10.1186/s12871-018-0532-6.
    1. Meng L, Li L, Lu S, et al. The protective effect of dexmedetomidine on LPS-induced acute lung injury through the HMGB1-mediated TLR4/NF-κB and PI3K/Akt/mTOR pathways. Mol Immunol. 2018;94:7–17. doi: 10.1016/j.molimm.2017.12.008.
    1. Conti G, Ranieri VM, Costa R, et al. Effects of dexmedetomidine and propofol on patient-ventilator interaction in difficult-to-wean, mechanically ventilated patients: a prospective, open-label, randomised, multicentre study. Crit Care. 2016;20:206. doi: 10.1186/s13054-016-1386-2.
    1. Reade MC, Eastwood GM, Bellomo R, et al. Effect of Dexmedetomidine added to standard care on ventilator-free time in patients with agitated delirium: a randomized clinical trial. JAMA. 2016;315:1460–1468. doi: 10.1001/jama.2016.2707.
    1. Grant MJC, Schneider JB, Asaro LA, et al. Dexmedetomidine use in critically ill children with acute respiratory failure. Pediatr Crit Care Med. 2016;17:1131–1141. doi: 10.1097/PCC.0000000000000941.
    1. Gu H, Bai J, Liu J. Effects of dexmedetomidine versus propofol on SPO2 in children with tetralogy of fallot during anesthesia. Int J Clin Exp Med. 2015;8:22550–22556.
    1. Meng PZ, Liu J, Hu PS, Tong F. Protective effect of Dexmedetomidine on endotoxin-induced acute lung injury in rats. Med Sci Monit. 2018;24:4869–4875. doi: 10.12659/MSM.908887.
    1. Defresne AA, Hans GA, Goffin PJ, et al. Recruitment of lung volume during surgery neither affects the postoperative spirometry nor the risk of hypoxaemia after laparoscopic gastric bypass in morbidly obese patients: a randomized controlled study. Br J Anaesth. 2014;113:501–507. doi: 10.1093/bja/aeu101.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren